Get started
Author

Marcus Maximillian Ilg

Observed names: Ilg Dr. Marcus M, Ilg, Marcus, Ilg, Marcus M., M. Ilg, M.M. Ilg, Marcus Ilg, Marcus M Ilg, Marcus M. Ilg, Mm Ilg
ORCID: 0000-0003-0803-0610
Observed ORCID: 0000-0003-0803-0610
OpenAlex ID: A5045733440
The Complete Genome Sequence of Clostridium aceticum: a Missing Link between Rnf- and Cytochrome-Containing Autotrophic Acetogens
2015 · Anja Poehlein, Martin Cebulla, et al. · mBio · 84
A Dynamic Role of TBX3 in the Pluripotency Circuitry
2015 · Ronan Russell, Marcus Ilg, et al. · Stem Cell Reports · 67
PDF
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models
2018 · Marcus M. Ilg, Marta Mateus, et al. · European Urology · 52
PDF
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease
2019 · Uros Milenkovic, Marcus M. Ilg, et al. · Sexual Medicine Reviews · 47
Simvastatin and the Rho‐kinase inhibitor Y‐27632 prevent myofibroblast transformation in Peyronie's disease‐derived fibroblasts via inhibition of YAP/TAZ nuclear translocation
2018 · Uros Milenkovic, Marcus M. Ilg, et al. · British Journal of Urology · 40
PDF
Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease
2020 · Marcus M. Ilg, Simon J. Stafford, et al. · The Journal of Sexual Medicine · 26
PDF
Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie’s Disease
2018 · Marta Mateus, Marcus M. Ilg, et al. · The Journal of Sexual Medicine · 25
European Society for Sexual Medicine Consensus Statement on the Use of the Cavernous Nerve Injury Rodent Model to Study Postradical Prostatectomy Erectile Dysfunction
2020 · Emmanuel Weyne, Marcus M. Ilg, et al. · Sexual Medicine · 21
PDF
TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation
2024 · Marcus M. Ilg, Stephen A. Bustin, et al. · Scientific Reports · 12
Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease
2022 · Marcus M. Ilg, Alice R. Lapthorn, et al. · PLoS ONE · 12
PDF
What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs?
2019 · U Milenkovic, Mm Ilg, et al. · Expert Opinion on Emerging Drugs · 12
PDF
European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie’s disease
2023 · Fabio Castiglione, Onur Ö Çakır, et al. · Sexual Medicine · 10
PDF
Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars
2022 · Alice Ruth Lapthorn, Marcus Maximillian Ilg, et al. · European Journal of Pharmacology · 10
PDF
A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie’s disease: the first clinical signals
2023 · Selim Cellek, Matthew Megson, et al. · The Journal of Sexual Medicine · 9
Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts
2025 · Marcus M. Ilg, Alice R. Lapthorn, et al. · Frontiers in Pharmacology · 6
PDF
Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie’s disease
2023 · Marcus M Ilg, David J Ralph, et al. · The Journal of Sexual Medicine · 5
PDF
Unwinding Fibrosis in Peyronie's Disease
2020 · Marcus M. Ilg, Selim Cellek · The Journal of Sexual Medicine · 5
Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease
2024 · Sophie L. Harding, Marcus M. Ilg, et al. · British Journal of Urology · 4
PDF
Temporal gene signature of myofibroblast transformation in Peyronie’s disease: first insights into the molecular mechanisms of irreversibility
2024 · Marcus M Ilg, Sophie Harding, et al. · The Journal of Sexual Medicine · 4
Hydroxypyridone anti-fungals selectively induce myofibroblast apoptosis in an in vitro model of hypertrophic scars
2024 · Alice Ruth Lapthorn, Marcus Maximillian Ilg, et al. · European Journal of Pharmacology · 3
(109) Confirming Anti-fibrotic Effect of Terfenadine, Ebastine, and Solifenacin in in Vitro Models of Peyronie’s Disease
2023 · Ilg Dr. Marcus M, Lapthorn Dr. Alice R, et al. · The Journal of Sexual Medicine · 2
PDF
Discovery of novel anti-fibrotics through phenotypic screening
2025 · Alice R. Lapthorn, Sophie L. Harding-Fox, et al. · Drug Discovery Today · 1
(118) the Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in Preventing Myofibroblast Transformation in in Vitro Models of Peyronie’s Disease
2023 · Harding Sophie L, Ilg Dr. Marcus M, et al. · The Journal of Sexual Medicine · 1
PDF
Investigating the Role of Extracellular Vesicles in Peyronie's Disease
2022 · Marcus Ilg, Paul Dyer, et al. · The Journal of Sexual Medicine · 1
Statins Synergize with Other Drugs to Prevent Myofibroblast Transformation in In Vitro Model of Peyronie's Disease
2022 · Marcus Ilg, David Ralph, et al. · The Journal of Sexual Medicine · 1
Works count: 49
Citation count: 461
H-index: 11
I10-index: 12
Year
Topic
Type